UW School of Medicine and Public Health: New injectable gel offers promise for tough-to-treat brain tumors

Like the hardiest weed, glioblastoma almost always springs back — usually within months after a patient’s initial brain tumor is surgically removed. That is why survival rates for this cancer are just 25 percent at one year and plummet to 5 percent by the five-year mark.

One of the challenges of treating this disease is that surgeons can’t always remove every bit of tumor or glioma stem cells that might linger in the brain.

. . .

Hu’s Cell-Inspired Personalized Therapeutic (CIPT) Lab has developed a powerful immunity-boosting postoperative treatment that could transform the odds for patients with glioblastoma. Hu and his collaborators published their research on the treatment’s use in mouse models of human glioblastoma this month in the journal Science Translational Medicine.

Read the full article here